Clinical study on MEAD regimens for relapsed or refractory adult patients with acute lymphocyte leukemia

VernacularTitle:MEAD方案治疗难治复发性成年人急性淋巴细胞白血病
Author: Wanhong ZHAO ; Wanggang ZHANG ; Xingmei CAO ; Yinxia CHEN ; Aili HE ; Fang HUANG ; Jie LIU ; Xiaorong MA ; Jianli WANG ; Yun YANG
Publication Type:Journal Article
Keywords: Leukemia,lymphocytic,acute; Adult; Antineoplastic combined chemotherapy protocols
From:Journal of Leukemia & Lymphoma 2010;19(6):349-351
CountryChina
Language:Chinese
Abstract: Objective To study the clinic effect and safety of MEAD chemotherapy regimen for adult patients with relapsed or refractory acute lymphocyte leukemia. Methods Between July 2006 and July 2009,twenty-two adult patients with relapsed or refractory acute lymphocyte leukemia received MEAD regimen (mitoxantrone 6 mg/d dl-3 iv drip,cytarabine 100 mg/d dl-5 iv drip,etoposide 100 mg/d dl-5 iv drip,dexmethasone 10 mg/d dl-8 iv drip). Results The complete remission (CR) rate of adult patients with relapsed or refractory acute lymphocyte leukemia was 31.8 %,the partial remission(PR) rate was 22.7 % and the overall response (OR) rate 54.5 %. The cumulitive CR rate was 50.0 %,and the PR rate 40.9 % after two times MEAD chemotherapy regimen. The main adverse effect was different level of myelosuppression,and other toxicity of vital organ was mild. Conclusion MEAD regimen is effective and can be tolerated for adult patients with relapsed or refractory acute lymphocyte leukemia,and its side effect is mild.